Betoptic Eye Drops 0.5%

Pays: Jordanie

Langue: anglais

Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Ingrédients actifs:

Betaxolol 0.5 %

Disponible depuis:

شركة مستودع الأدوية الأردني - The Jordan Drugstore Co

Code ATC:

S01ED02

DCI (Dénomination commune internationale):

Betaxolol 0.5 %

Dosage:

0.5%

Unités en paquet:

5 ml

Fabriqué par:

ALCON-COUVREUR N.V/BELGIUM (بلجيكا)

Descriptif du produit:

2.53 :سعر الجمهور + الضريبة

Notice patient

44836-1
1111111111111
111111
I
I
I
I
I
BETOPTIC®
5
mg/ml,
eye
drops,
solution
1.
NAME
OF
THE
MEDICINAL
PRODUCT
BETOPTIC"
5
mg/ml,
eye
drops,
solution.
2.
QUAUTATIVE.AND
QUANTITATIVE
COMPOSITION
5.6
mg/ml
Betaxolol
hydrochloride
eq.
betaxolol
base
5
mg/ml.
For
excipients,
see
6.1.
3.
PHARMACEUTICAL
FORM
Eye
drops,
solution.
4.
CUNICAL
PARTICULARS
4.1
TherapeuUc
indications
Indicated
in
patients
with
chronic
open-angle.
glaucoma.
II
may
be
used
alone
or
in
combination
with
other
intraocular
pressure
lowering
medications.
4.2
Posology
and
method
of
administration
_The _
usual
dose
is
'one
drop
in
the
affected
eyers)
twice
daily.
In
some
patients,
the
intraocular
.
pressure
.
lowering
response
may
require
a
few
weeKs
to
stabilise.
The
intraocular
pressure
should
therefore
be
determined
during
the
first
month
of
treatment.
Thereaf·
ter,
the
frequency
of
measurement
should
be
determined
by
the
physiCian.
Because
of
variations
of
intraocular
pressure
in
some
patients,
satisfactory
response
to
twice
a
day
therapy
is
best
determined
by
measuring
intraocular
pressure
at
different
times
during
the
day.
If
the
intraocular
pressure
of
the
patient
is
not
adequately
controlled
on
this
regimen,
concomitant
therapy
wHh
other
intraocular.
pressure
lowering
medications
[including
pilocarpine,
other
miotics,
epinephrine
or
systemically
administered
carbonic
anhydrase
inhibitors
J
can
be
instnuted.
Therapy
should
be
individualised
for
optimal
control
of
glaucoma
in
each
patient.
To
switch
a
patient
from
a
single
anti-glaucoma
agent
to
a
trealment
WITh
BETOPTIC'"
eye
drops,
continue
the
initial
medication
and
add
one
drop
of
BETOPTIC"
eye
drops
twice
a
day.
On
the
following
day,
,
discontinue
the
initial
medication
completely
and
continue
the
treat·
ment
wtih
BETOPTIC"
eye
drops.
~
Caution
should
be
exercised
in
the
treatment
of
glaucoma
patients
with
excessive
restriction
of
pulmonary
function.
There
have
been
reports
of
asthmatic
attacks
and
pulmonary
distress
during
betaxolol
treatment.
Although
rechallenges
of
some
such
patient